Archer Materials Ltd (ASX:AXE) (OTCMKTS:ARRXF) (FRA:38A) has made progress in the development of its biochip by establishing essential chip testing operations in a semiconductor fabrication environment.
This is an essential step in developing and commercialising the company’s biochip technology.
Earlier the company achieved the ability to analyse individual materials in the components of the biochip and now has progressed to the stage where it has established testing and measurement for the chips themselves.
Shares of the company have been almost 4.2% higher intra-day to A$0.76 while its market cap at the start of the day was approximately A$165 million.
“Key operational requirement”
Archer CEO Mohammad Choucair said: “The establishment of in-house semiconductor chip testing and measurement is a key operational requirement that is necessary to build our technology.
“This will allow the company to meet a number of milestones in the development of multiple chip types, including its biochip and also quantum computing chip.”
According to the company, the global semiconductor industry is one of the most important drivers of the global economy as it is the basis of almost all technology.
Core components of technology
Archer has recently expanded access to institutional deep tech infrastructure to analyse and characterise the material properties of its devices.
READ: Archer Materials strategically expands access to institutional deep tech infrastructure
The chip testing capabilities established are an integral part of prototyping and biochip operation, whereby testing occurs after the chip component assembly to assess operation.
This new capability provides the high-quality and reliable technical specifications necessary for Archer’s future patent applications.
Access to deep tech infrastructure allows Archer to build its chip technologies, including a graphene-based biochip for point-of-care medical diagnostics, and also allows the company to qualify its semiconductor device production processes as it advances towards sub-10 nm biochip feature sizes.
Biochip development milestones
The establishment of semiconductor chip testing allows Archer to reach a number of biochip development milestones, including the fabrication of graphene transistors and their operation at the limits of what can be achieved technologically.
The company is developing advanced chips in the same semiconductor fabrication environment.
Importantly, the chip testing workstations can also be configured to test chip devices relevant to the company’s 12CQ quantum computing qubit processor development.